Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Binimetinib CAS 606143-89-9

Binimetinib CAS 606143-89-9

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 606143-89-9

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15 days

Payment Terms: T/T, L/C, D/A, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
606143-89-9
Appearance::
White To Off White Solid
Molecular Formula::
C17H15BrF2N4O3
Molecular Weight::
441.22700
EINECS NO::
639-995-7
MDL NO::
MFCD06143899
CAS NO::
606143-89-9
Appearance::
White To Off White Solid
Molecular Formula::
C17H15BrF2N4O3
Molecular Weight::
441.22700
EINECS NO::
639-995-7
MDL NO::
MFCD06143899
Binimetinib CAS 606143-89-9

Product Description:

Product Name: binimetinib CAS NO: 606143-89-9

 

 

 

Synonyms:

hydroxyethoxy)amide;

MEK-162;

 

 

 

Chemical & Physical Properties:

Appearance: White to off white solid

Assay: ≥98.0%

Density: 1.67

Storage Condition: Dry, dark and at 0 - 4 ℃for short term (days to weeks) or -20 ℃for long term (months to years).

Solubility: Soluble in DMSO

 

 

 

Safety Information:

Caution Statements: P261-P305+P351+P338

Signal Word: Warning

Hazard Statements: H302-H315-H319-H335

Storage: Powder -20℃ 3 years 4℃2 years ;In solvent -80℃ 6 months -20℃ 1 month

 

 

 

Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.

It can be taken orally in tablet form.

In 2015 it was in phase 3 clinical trials for ovarian cancer, BRAF mutant melanoma, and NRAS Q61 mutant melanoma.

In Dec 2015 the company announced that the mutant-NRAS melanoma trial was successful. In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment. NDA submitted Jun 2016.

In April 2016 it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.

 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.